Lesabelimab

Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor[1][2].

Product Specifications

CAS Number

[2475402-56-1]

Product Name Alternative

LDP

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/lesabelimab.html

Purity

97.34

Solubility

10 mM in DMSO

Smiles

[Lesabelimab]

Molecular Weight

(144.76 kDa)

References & Citations

[1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 35, No. 4, 2021.|[2]Masugi Y, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2017 Aug;66 (8) :1463-1473.